Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.


Explore Compare Share


Clinuvel Pharmaceuticals (CUV.AX)



Last Signal:


Trading: HOLD @ $24.57
Signal Strength: MEDIUM

Clinuvel Pharmaceuticals (ASX:CUV) current accumulation has given strength to the share price and the continuation of bullish trading conditions. Currently, the DVI is 477.

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.

The daily volume index (DVI) is the amount of individual securities traded in a day on average over a specified period of time. Trading activity relates to the liquidity of a security. When average daily trading volume is high the stock can be easily traded and has high liquidity if trading volume is not very high and the security will tend to be less expensive because people are not as willing to buy it. As a result average daily trading volume can have an effect on the price of the security.

Calculation: Daily Volume Index (DVI):
1) [Close]-[Average price] / [Average price] x [Volume];

PROFILE: Clinuvel Pharmaceuticals (CUV.AX)

Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Daily Volume Index

Download button icon Download
Company Close Change (%) Volume Value Signal
LOV Lovisa 9.3 20.2 1,518,896 803 BULLISH CROSSOVER
OSP Osprey Medical 0.11 4.8 5,000 506 BULLISH CROSSOVER
CGF Challenger Financial Services 7.7 3.5 2,624,869 128 BULLISH CROSSOVER
IDX Integral Diagnostics 3 1.4 34,851 73 BULLISH CROSSOVER
AKP Audio Pixels Holdings 22 0.9 12,465 26 BULLISH CROSSOVER
SLK Sealink Travel 4 0.5 171,547 171 BULLISH CROSSOVER
RCR RCR Tomlinson 0.87 0 0 1,319 BULLISH CROSSOVER
BAF Blue Sky Alternatives 0.86 0 143,240 19 BULLISH CROSSOVER
IFT Infratil 3.8 0 0 327 BULLISH CROSSOVER
IRD Iron Road 0.07 0 26,845 2,987 BULLISH CROSSOVER
back to top